SEEK: Salford Environment for Expertise and Knowledge
Dr Niroshini Nirmalan
Dr Niroshini Nirmalan
postal addressG24 Peel Building, University of Salford, Manchester, M5 4WT.
Key Memberships
From March 2010 to present.
Full Member of Research Centre: Biomedical Research Centre
From September 2015 to present.
Full Member of Research Centre: Parasitology & Disease
From March 2010 to August 2015.
Profile Summary

Malaria continues to inflict a heavy mortality and morbidity burden with up to 3 million annual fatalities globally. Despite significant post-genomic technical advances, drug development has struggled compete with resistance acquisition. My research interests focus on drug discovery/screening and the development of proteomic/mass spectrometric methods to define mechanisms of antimalarial drug action. The emergence of resistance to the current frontline drug Artemisinin and the absence of affordable alternatives in the developmental pipeline make it imperative to explore new options for antimalarial drug discovery.

The Malaria Proteomics Laboratory at the University of Salford is currently screening a range of compounds for potential antimalarial properties. The main areas of investigation are summarized below:

Drug repositioning or re-purposing, whereby existing FDA approved drugs already used in other diseases are screened for antimalarial activity. The strategy affords a fast tracked route to discover new antimalarial options as well as synergistic compounds which could be used in combination with current frontline drugs impede the progress of resistance. Fluorescence-based in vitro drug susceptibility assays optimized in the laboratory are used in the preliminary screens.

A second research strategy focuses on the investigation of a range of natural product options for antimalarial efficacy. A collaborative project with the National Institute for Pharmaceutical research and development (NIPRD, Nigeria) is currently exploring a series of ‘traditional fever cures’ for in vitro antimalarial activity. Potential leads are taken forward for bioassay guided fractionation and active compound isolation. Fractionation end points will be guided by proteomic/mass spectrometric parameters to improve on currently available drug susceptibility assays which are largely reliant on parasite death, a crude and late measure of antimalarial efficacy.

Key Qualifications
Key Projects
Warhurst/Carlson Laboratory support costs 2019-2020 (ELRB50 extension)
Salford Royal Hospitals NHS Trust, 43,093.00.
Principal Investigator: N Nirmalan (100%).
Commonwealth Split-site PhD Scholarship
Department for International Development, 20,944.00.
Principal Investigator: N Nirmalan (100%).
Funding of a research technician post based at Salford Royal Foundation Trust (Pamela Davies)
Salford Royal NHS Foundation Trust, 42,251.00.
Principal Investigator: N Nirmalan (100%).
Warhurst/Carlson Laboratory Support Costs 2017-2018 (ELRB50 Extension)
Salford Royal NHS Foundation Trust, 40,903.00.
Principal Investigator: N Nirmalan (100%).
Warhurst/Carlson Laboratory Support Costs 2016-2017
Salford Royal NHS Foundation Trust, 40,626.00.
Principal Investigator: N Nirmalan (100%).
Biomedical Vacation Scholarship
Wellcome Trust, 2,000.00.
Principal Investigator: N Nirmalan (100%).
Biomedical Studentship
Wellcome Trust, 1,440.00.
Principal Investigator: N Nirmalan (100%).
Investigating cryopreservative options for cell line freezing
Technology Strategy Board, 4,500.00.
Principal Investigator: N Nirmalan (100%).
Key Publications
Refereed Journal Articles
Guest Editorials in Journals
Guest Editorships of Journals